Features | Partner Sites | Information | LinkXpress
Sign In
PURITAN MEDICAL
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Common Anti-Inflammatory Drugs Associated With Decreased Risk of Skin Cancer

By BiotechDaily International staff writers
Posted on 12 Jun 2012
A new study has found an association linking the use of various nonsteroidal anti-inflammatory drugs (NSAIDs) with a decreased risk of two major types of skin cancer.

Researchers at Aarhus University Hospital (Aarhus, Denmark) undertook a retrospective, population-based case-control study of patients in Northern Denmark to examine the association between use of NSAIDs--including aspirin, ibuprofin, and naproxen--and the risk of squamous cell carcinoma (SCC), basal cell carcinoma (BCC), and malignant melanoma (MM). Analysis of medical records from northern Denmark from 1991 through 2009 identified 1,974 diagnoses of SSC, 13,316 diagnoses of BCC, and 3,242 diagnoses of MM. Drug use information (including prescription data) from these patients was compared with information from 178,655 individuals without skin cancer.

Statistical analyses indicated that individuals who filled more than two prescriptions for NSAIDs had a 15% decreased risk for developing SCC and a 13% decreased risk for developing MM than those who filled two or fewer prescriptions for the medications, especially when the drugs were taken for seven or more years or taken at high intensity. Taking NSAIDs did not seem to reduce the risk of developing BCC in general, although there was a 15% and 21% reduced risk of developing BCC on less-exposed sites (body areas other than the head and neck) when the drugs were taken long term or at high intensity, respectively.

The main SCC and MM risk-reducers in the study were nonselective NSAIDs and older COX-2 inhibitors (diclofenac, etodolac, and meloxicam). NSAIDs are thought to help prevent the development of cancer by inhibiting cyclooxygenase (COX) enzymes, which are known to be involved in carcinogenesis.

“We hope that the potential cancer-protective effect of NSAIDs will inspire more research on skin cancer prevention,” said first author Sigrún Alba Jóhannesdóttir, BSc, of the Department of Clinical Epidemiology at Aarhus University Hospital; “Also, [this] effect should be taken into account when discussing benefits and harms of NSAID use.”

Related Links:
Aarhus University Hospital



Channels

Genomics/Proteomics

view channel
Image: Researchers have generated disease-free stem cells from patients with mitochondrial disease that can be converted into any cell type including neuronal progenitors (left) or heart cells (right). These could potentially be used for future transplantation into patients (Photo courtesy of Salk Institute of Biological Studies).

Methods Developed to Generate Normal Stem Cells from Patients with Mitochondrial Defects

A recent paper described two methods for converting cells from patients with mitochondrial defects into normal pluripotent stem cells that could be induced to differentiate into several different types of tissues.... Read more

Drug Discovery

view channel
Image: A new micelle delivery system for the protective polyphenols resveratrol and quercetin (mRQ) may have value in cancer chemotherapy (Photo courtesy of Oregon State University).

Micelles Containing Resveratrol and Quercetin Reverse Doxorubicin Cardiotoxicity

Cancer researchers blocked the toxic effects of the cancer drug doxorubicin (DOX) by administering it together with the plant antioxidants resveratrol and quercetin. Although in use for more than 40... Read more

Lab Technologies

view channel
Image: The Leica DM2500 LED Microscope for clinical laboratories and research applications (Photo courtesy of Leica Microsystems).

New LED Microscope Completes Line of Clinical and Research Tools

A popular microscope used for both clinical and research applications is now available with LED illumination. The Leica (Wetzlar, Germany) DM2500 and DM2500 LED microscopes represent a class of tools... Read more

Business

view channel

Teva Buys Allergan Generic Business Unit

Teva Pharmaceutical Industries (Petah Tikva, Israel) has bought the Allergan (Irvine, CA, USA) generic drugs business for USD 40.5 billion in cash and stock, solidifying its position as the world's largest generic drug maker. Under the terms of the agreement, Teva will pay USD 33.75 billion in cash and USD 6.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.